Advertisement

cancer immunotherapy

cancer immunotherapy

  • Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials

Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials

, , |

Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.

Assessing Antigen-Specific T Cell Functionality With Dendritic Cell/CD8⁺ T Cell Co-Culture

On December 12, 2023, STEMCELL Technologies' Dr. Catherine Ewen described, in detail, how to set up DC (dendritic cell) and CD8ᐩ T cell co-culture experiments that generate antigen-specific CD8ᐩ T cells, and how to assess CD8ᐩ T cell proliferation, functionality, and killing activity. In this Q&A report, you can read her answers to questions asked by the audience. Answers have been edited for length and/or clarity.

Exploring Predictive Biomarkers and ERK1/2 Phosphorylation: A New Horizon in Forecasting Survival and Response to Immune Checkpoint Blockade in Glioblastoma Treatment

, , , , , , |

In this webinar, Victor Arrieta highlights the link between p-ERK activation and improved survival in rGBM patients using anti-PD-1 immunotherapy.

  • CrownBio Cancer-Immunity Cycle Blog FI

The Cancer-Immunity Cycle: Research Solutions for Preclinical Immuno-Oncology

News, Scientific Articles|

Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.

Go to Top